Fresh analysis reveals that people who discontinue new weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who stop traditional lifestyle regimens.
Published data in a major medical journal shows that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing these treatments should be cognizant of the risk of fast rebound weight gain when the therapy ends," stated researcher Dr. Susan Jebb.
This pace of regain suggests a reversion to original mass within about one and a half years.
Analyzing Approaches
The analysis, which reviewed dozens of trials involving over 9,000 of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists note that individuals who lose weight through lifestyle changes alone usually see a more gradual weight regain—around 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Experts suggest the way of the jabs accounts for the accelerated regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' means appetite is no longer kept in check, making overeating a significant risk."
A Chronic Condition?
The NHS recommend the jabs for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, given the likelihood of weight regain, the treatment might need to be life-long.
This view is reinforced by pharmaceutical companies, who note that the findings "emphasize the chronic nature of obesity," similar to managing diseases like hypertension.
Patient Accounts
Individuals who have stopped the jabs describe a powerful resurgence of hunger.
"I experienced a trigger that goes on and you're instantly starving," recalled a patient.
This challenge is worsened if patients have not established sustainable dietary or behavioural modifications during therapy.
Widespread Adoption
Survey data indicate that a significant number of people in the UK have used these injections in the past year, with desire remaining high.
- Use is more common among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers emphasize that while the jabs are effective tools for shedding pounds, they are not a standalone solution and maintained weight loss relies on integrated lifestyle management.
